The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
Authors
Keywords
-
Journal
Scientific Reports
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-16
DOI
10.1038/s41598-021-85385-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients
- (2020) Bruno Carvalho et al. JOURNAL OF NEURO-ONCOLOGY
- Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
- (2020) Yolla Haibe et al. Frontiers in Oncology
- EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma
- (2019) Koos E. Hovinga et al. JOURNAL OF NEURO-ONCOLOGY
- Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab
- (2019) R. A. Manneh Kopp et al. Clinical & Translational Oncology
- A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
- (2019) Martin van den Bent et al. JOURNAL OF NEURO-ONCOLOGY
- Cerebral blood volume and apparent diffusion coefficient – Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma
- (2019) Lucie Petrova et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
- (2018) Yazhuo Zhang et al. Molecular Cancer
- Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
- (2018) Seung Won Choi et al. Cancer Medicine
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
- (2017) Roger Stupp et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine–DNA Methyltransferase Biomarker Analyses
- (2017) Timothy Cloughesy et al. JOURNAL OF CLINICAL ONCOLOGY
- Histopathological vascular investigation of the peritumoral brain zone of glioblastomas
- (2017) Ryota Tamura et al. JOURNAL OF NEURO-ONCOLOGY
- Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
- (2017) Carlos Bais et al. JNCI-Journal of the National Cancer Institute
- Lomustine and Bevacizumab in Progressive Glioblastoma
- (2017) Wolfgang Wick et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
- (2017) Carlos Bais et al. JNCI-Journal of the National Cancer Institute
- Histopathological investigation of glioblastomas resected under bevacizumab treatment
- (2016) Ryota Tamura et al. Oncotarget
- Can We Predict Bevacizumab Responders in Patients With Glioblastoma?
- (2015) Tina M. Mayer JOURNAL OF CLINICAL ONCOLOGY
- Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial
- (2015) Thomas Sandmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma
- (2015) Tobias Kessler et al. Oncotarget
- Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study
- (2015) Bruno F. Carvalho et al. Oncology Research and Treatment
- Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies
- (2014) Kathryn M. Field et al. CANCER
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- (2014) Walter Taal et al. LANCET ONCOLOGY
- Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target
- (2014) R. Stupp et al. NEURO-ONCOLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition
- (2013) Y. Zhang et al. CLINICAL CANCER RESEARCH
- Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
- (2013) A. Jahangiri et al. CLINICAL CANCER RESEARCH
- Glioblastoma Resistance to Anti-VEGF Therapy: Has the Challenge Been MET?
- (2013) J. H. McCarty CLINICAL CANCER RESEARCH
- Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma
- (2013) Emeline Tabouret et al. NEURO-ONCOLOGY
- Biomarkers to predict the clinical efficacy of bevacizumab in cancer
- (2010) Adrian M Jubb et al. LANCET ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- Biomarkers of response and resistance to antiangiogenic therapy
- (2009) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme
- (2009) M. H. Cohen et al. ONCOLOGIST
- Prognostic significance of c-Met expression in glioblastomas
- (2008) Doo-Sik Kong et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now